List the effects of stimulation of adrenoreceptors on target organs and tissues (60% marks). Describe the mechanism of action and pharmacokinetics of metoprolol (40% marks).
This question required a list of effects of the stimulation of adrenoreceptors, thus detailed description of downstream effects and exact mechanisms was not required. Using a systems based structure with a subdivision into each receptor (or vice versa) meant that important GIT, GUT, endocrine and metabolic effects were not omitted. Given the need for little depth, this part of the question required breadth particularly within cardiovascular effects. Venoconstriction, dromotropy and lusitropic effects should also be covered. The second part of the question required a detailed description of the mechanism of action and pharmacokinetics only, thus dose, pharmaceutics and pharmacodynamic information was not required. Here it would be important to elaborate on the downstream effects of blocking the beta adrenergic receptors as compared with the information required in the first part of the question.
Adrenoceptor activation:
Metoprolol:
| Name | Metoprolol |
| Class | Beta blocker |
| Chemistry | aryloxypropanolamine |
| Routes of administration | Oral or IV |
| Absorption | 50% oral bioavailability |
| Solubility | pKa 9.7, poor lipid solubility |
| Distribution | VOD 2.8-4.8 L/kg; only 12% protein bound |
| Target receptor | Selective β1 receptor blocker |
| Metabolism | Mainly hepatic clearance |
| Elimination | minimal renal excretion; half-life 3-4 hrs |
| Time course of action | Clinical effects persist for longer than the half life would suggest, because they are mainly determined by drug-receptor affinity |
| Mechanism of action | By binding to Gs-protein coupled β1 receptors, blocks cAMP synthesis |
| Clinical effects | β1 effects: decreased heart rate, cdecreased contractility, decreased blood pressure, lower myocardial oxygen demand and increased diastolci coronary fillng, and decreased arrhythmogenicity. |
| Single best reference for further information | Oliver et al (2019) |
William Tank, A., and Dona Lee Wong. "Peripheral and central effects of circulating catecholamines." Comprehensive Physiology 5.1 (2011): 1-15.
Motiejunaite, Justina, Laurence Amar, and Emmanuelle Vidal-Petiot. "Adrenergic receptors and cardiovascular effects of catecholamines." Annales D'endocrinologie. Vol. 82. No. 3-4. Elsevier Masson, 2021.
Levitzki, Alexander. "Catecholamine receptors." Reviews of Physiology, Biochemistry and Pharmacology, Volume 82 (1978): 1-26.
Ciccarelli, M., et al. "Adrenergic receptors." Endocrinology of the Heart in Health and Disease (2017): 285-315.
Sannerstedt, R., and H. Wasir. "Acute haemodynamic effects of metoprolol in hypertensive patients." British Journal of Clinical Pharmacology 4.1 (1977): 23-26.
Frishman, William H., and Elijah Saunders. "β‐adrenergic blockers." The Journal of Clinical Hypertension 13.9 (2011): 649.
Frishman, William H. "β-Adrenergic blockers." Medical Clinics of North America 72.1 (1988): 37-81.